Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Vertex races to FDA after phase 3 kidney disease data impress analysts

Vertex races to FDA after phase 3 kidney disease data impress analysts

  • March 10, 2026

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval in November.

Leave A Comment

Fields (*) Mark are Required